BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 18848503)

  • 1. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
    Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P;
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
    Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
    Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.
    Dalaker M; Bonesrønning JH
    J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):277-82. PubMed ID: 19207642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
    Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
    Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
    Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
    Schneeweiss S; Korzenik J; Solomon DH; Canning C; Lee J; Bressler B
    Aliment Pharmacol Ther; 2009 Aug; 30(3):253-64. PubMed ID: 19438424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.
    Pearce CB; Lawrance IC
    J Gastroenterol Hepatol; 2007 Oct; 22(10):1671-7. PubMed ID: 17845695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study.
    Katsanos KH; Vermeire S; Christodoulou DK; Riis L; Wolters F; Odes S; Freitas J; Hoie O; Beltrami M; Fornaciari G; Clofent J; Bodini P; Vatn M; Nunes PB; Moum B; Munkholm P; Limonard C; Stockbrugger R; Rutgeerts P; Tsianos EV;
    Digestion; 2007; 75(2-3):113-21. PubMed ID: 17598963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
    Gheorghe L; Gheorghe C; Badea M; Vădan R; Pârvulescu I; Toader C; Tugui L; Papuc O; Ionescu R; Preda C; Călin I; Diculescu M
    Rom J Gastroenterol; 2003 Mar; 12(1):7-13. PubMed ID: 12673373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.
    Menter A; Reich K; Gottlieb AB; Bala M; Li S; Hsu MC; Guzzo C; Diels J; Gelfand JM
    J Drugs Dermatol; 2008 Dec; 7(12):1137-46. PubMed ID: 19137767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
    Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Chen DM; Pritchard ML; Sandborn WJ
    Clin Gastroenterol Hepatol; 2006 May; 4(5):621-30. PubMed ID: 16678077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk for demyelinating diseases in patients with inflammatory bowel disease.
    Gupta G; Gelfand JM; Lewis JD
    Gastroenterology; 2005 Sep; 129(3):819-26. PubMed ID: 16143121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of infliximab in 10 years of clinical practice.
    O'Donnell S; Murphy S; Anwar MM; O'Sullivan M; Breslin N; O'Connor HJ; Ryan BM; O'Morain CA
    Eur J Gastroenterol Hepatol; 2011 Jul; 23(7):603-6. PubMed ID: 21602689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates?
    Cannom RR; Kaiser AM; Ault GT; Beart RW; Etzioni DA
    Am Surg; 2009 Oct; 75(10):976-80. PubMed ID: 19886148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.
    Brackmann S; Andersen SN; Aamodt G; Langmark F; Clausen OP; Aadland E; Fausa O; Rydning A; Vatn MH
    Scand J Gastroenterol; 2009; 44(1):46-55. PubMed ID: 18609187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab in the surgical management of complex fistulating anal Crohn's disease.
    Talbot C; Sagar PM; Johnston MJ; Finan PJ; Burke D
    Colorectal Dis; 2005 Mar; 7(2):164-8. PubMed ID: 15720356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.